Severe chronic immune-mediated peripheral nerve myelinopathies frequently lead to profound physical disability and intractable neuropathic symptoms. When conventional immunotherapies fail, clinicians face substantial challenges in halting disease progression. However, a landmark breakthrough demonstrates that targeted bispecific T-cell redirection can reverse persistent axonal injury. Emerging clinical data highlight the transformative potential of targeted T-cell engagement in treatment-refractory autoimmune neuropathy.

The Clinical Dilemma in Refractory Autoimmune Neuropathy

Chronic immune-mediated peripheral nerve myelinopathies represent a heterogeneous cluster of disabling neuro-immunological disorders. For instance, anti-myelin-associated glycoprotein neuropathy and paraproteinemic neuropathies involve autoantibody-mediated destruction of myelin sheaths. Consequently, patients experience progressive sensory loss, severe ataxia, debilitating hand tremors, and debilitating motor weakness. Standard therapeutic regimens generally rely on intravenous immunoglobulin, plasma exchange, and systemic corticosteroids. Furthermore, clinicians often administer anti-CD20 monoclonal antibodies such as rituximab to eliminate circulating B lymphocytes. Unfortunately, a notable subset of patients remains completely refractory to these standard interventions. Traditional therapies fail primarily because they spare long-lived plasma cells residing in bone marrow niches. Because these antibody-producing cells lack surface CD20 expression, they continuously secrete pathogenic paraproteins unabated. Over several years, persistent neuroinflammation produces progressive secondary axonal degeneration and irreversible loss of ambulation. In addition, chronic physical impairment severely degrades daily quality of life and vocational productivity. Therefore, clinicians urgently require innovative therapeutic modalities that directly eliminate autoreactive plasma cell clones and arrest ongoing myelin breakdown.

Targeting BCMA with Bispecific T-Cell Engager Technology

To overcome therapeutic resistance, researchers have turned toward bispecific T-cell engager molecules originally designed for refractory hematological malignancies. Specifically, teclistamab represents an innovative bispecific antibody that simultaneously binds to CD3 on cytotoxic T cells and B-cell maturation antigen on plasma cells. B-cell maturation antigen exhibits strong, selective expression on late-stage B cells and antibody-secreting plasma cells. By forming an artificial immunological synapse, teclistamab redirects endogenous cytotoxic T lymphocytes to destroy these autoreactive plasma cell populations. Importantly, this mechanism bypasses classical major histocompatibility complex restriction. Unlike chimeric antigen receptor T-cell therapies, bispecific engagers offer an off-the-shelf formulation. Therefore, medical teams can administer the drug without extensive manufacturing delays or intense conditioning chemotherapy. In recent clinical evaluations, investigators administered teclistamab to two individuals suffering from aggressive, treatment-refractory peripheral nerve myelinopathies. The first patient presented with IgM-kappa paraprotein-associated neuropathy, while the second suffered from high-titer anti-MAG antibody-mediated neuropathy. Both patients had experienced steady neurological decline despite extensive prior immunotherapies. Thus, teclistamab provided a unique mechanism to deplete the pathological cellular reservoir driving their chronic disease.

Rapid Functional Recovery and Electrophysiological Regeneration

Following teclistamab administration, both patients experienced rapid and unprecedented functional recovery. Most remarkably, walking endurance improved substantially within weeks of therapy initiation. Patients who previously required ambulatory assistance or experienced debilitating gait ataxia regained stable, autonomous mobility. Concurrently, serial high-resolution nerve ultrasound examinations documented marked reductions in peripheral nerve swelling and fascicular edema. This structural resolution indicated prompt dampening of local intraneural inflammatory infiltration. Furthermore, serial electroneurography demonstrated objective electrophysiological regeneration. Investigators observed marked improvements in motor nerve conduction velocities, distal latencies, and compound muscle action potential amplitudes. Most notably, peripheral nerves that had demonstrated zero stimulus response at baseline examination regained detectable electrical activity during follow-up assessments. This re-emergence of nerve conduction directly confirmed functional remyelination and the recovery of conductible axons. Consequently, the objective clinical improvements matched the underlying structural restoration of peripheral nerve trunks. Such rapid neuromuscular revitalization stands in sharp contrast to the slow, incomplete recovery typically observed with conventional immunomodulatory drugs. Thus, bispecific engagers appear capable of facilitating profound peripheral nervous system repair.

Biomarker Dynamics and Paraprotein Elimination

Biomarker analyses provided compelling biological evidence explaining the observed clinical and electrophysiological improvements. Specifically, laboratory assays demonstrated rapid, complete clearance of circulating pathogenic antibodies. Serum IgM-kappa paraprotein in the first patient and high-titer anti-MAG autoantibodies in the second patient dropped below detection limits within six weeks of treatment initiation. Remarkably, these pathogenic proteins remained undetectable throughout the entire post-treatment surveillance period. Serum neurofilament light chain levels, which serve as a sensitive circulating biomarker of ongoing axonal damage, decreased in tandem with functional recovery. This sustained biochemical drop confirmed that teclistamab successfully halted ongoing neuroaxonal degeneration. Additionally, soluble B-cell maturation antigen concentrations declined sharply immediately after initial dosing, mirroring deep tissue plasma cell depletion. Interestingly, soluble antigen levels gradually re-emerged during extended follow-up, indicating repopulation by naive, non-pathogenic B-cell lineages. Nevertheless, pathogenic autoantibody titers remained completely negative during this period. Therefore, transient targeted plasma cell elimination induced a durable reset of humoral immune pathology without producing permanent marrow destruction.

Safety Profile and Neurological Practice Implications

The clinical trial results demonstrated remarkable tolerability alongside profound therapeutic efficacy. Notably, neither patient suffered serious adverse events, severe systemic infections, or high-grade cytokine release syndrome during teclistamab treatment. This favorable safety profile is particularly encouraging because severe systemic toxicity often complicates cytotoxic cell-based treatments. For neurologist teams managing recalcitrant neuro-immunological disorders, these findings open exciting therapeutic frontiers. Historically, treatment-refractory peripheral myelinopathies carried a dismal prognosis characterized by relentless functional impairment. Bispecific T-cell engager therapies deliver an accessible, off-the-shelf alternative to complex engineered cellular treatments. Moreover, clinicians can administer these constructs subcutaneously in specialized hospital settings without lengthy waiting periods. Although larger prospective clinical trials must confirm these findings, the deep remissions observed here suggest a paradigm shift. Targeted elimination of long-lived autoreactive plasma cells can reverse neuroaxonal destruction previously deemed irreversible. Consequently, neuro-immunologists should actively explore bispecific engagers for diverse antibody-mediated peripheral and central nervous system disorders. In the coming years, this therapeutic strategy could redefine standard care for patients who exhaust conventional immunotherapies.

Frequently Asked Questions

How does teclistamab work in autoimmune neuropathy?

Teclistamab is a bispecific antibody construct that redirects cytotoxic T cells to destroy B-cell maturation antigen-expressing plasma cells and mature B lymphocytes. Consequently, the therapy halts pathogenic autoantibody synthesis, rapidly clearing harmful paraproteins. This deep cellular depletion alleviates ongoing peripheral nerve inflammation and permits structural myelin repair.

Which patients with autoimmune neuropathy participated in this evaluation?

The study evaluated two individuals suffering from severe, treatment-refractory chronic immune-mediated peripheral nerve myelinopathies. Specifically, the first patient presented with IgM-kappa paraprotein-associated neuropathy, whereas the second patient had anti-MAG antibody neuropathy. Both individuals had experienced relentless functional deterioration despite conventional immunosuppressive regimens before receiving teclistamab.

What distinct clinical advantages do T-cell engagers offer over CAR-T therapies?

Unlike chimeric antigen receptor T-cell therapies, bispecific T-cell engagers represent off-the-shelf therapeutics requiring no patient-specific cell harvesting or genetic engineering delays. Furthermore, clinicians can administer these agents subcutaneously in standard specialized centers, dramatically accelerating therapy initiation for patients with rapidly progressive neuro-immunological disorders.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment and should not be relied upon as such. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Wickel J et al. Therapeutic effect of T-cell engager in two patients with autoimmune neuropathy. Nat Commun. 2026 May 30. doi: 10.1038/s41467-026-73819-1. PMID: 42218153.


2. Dalakas MC. Autoimmune neuropathies: advances in diagnosis and treatment. Curr Opin Neurol. 2023;36(5):455-462.


3. Querol L, Devaux J, Rojas-Garcia R, Illa I. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol. 2017;13(9):533-547.